research Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
Search
for
Sort by
Research
600-630 / 1000+ results
research Protein degradation: expanding the toolbox to restrain cancer drug resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
research Perspective Chapter: Repurposing Natural Products to Target COVID-19 – Molecular Targets and New Avenues for Drug Discovery
Natural products might help treat COVID-19, but current drugs like hydroxychloroquine haven't worked.
research Endoplasmic reticulum in health and disease: the 12th International Calreticulin Workshop, Delphi, Greece
The workshop discussed the role of a protein called calreticulin in health and disease, its potential as a treatment target, and its possible use as a disease marker.
research Treatment of Alopecia Areata With Tofacitinib
Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
research British Hair and Nail Society
The document concludes that scalp conditions have various causes and can present in many different ways.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
research Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Area Celsi: A Randomized Double-Blinded Parallel-Group Study
The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
Tofacitinib helped regrow hair in most patients with severe hair loss.
research Understanding autoimmunity of vitiligo and alopecia areata
Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata
A new mix of anthralin and calcipotriene might help treat severe hair loss.
research New therapies for alopecia areata
New treatments for severe alopecia areata show promise but lack standard approval.
research Emerging treatments in alopecia
New alopecia treatments aim for better results and fewer side effects.
research Combining 308-monochromatic excimer phototherapy with monthly IM triamcinolone acetonide for the treatment of resistant alopecia totalis
The combination therapy was effective and well-tolerated, especially in young patients.
research Efficacy of systemic minoxidil and tofacitinib combination in treatment‐resistant alopecia universalis
Using minoxidil and tofacitinib together can effectively treat severe hair loss.
research Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA
More severe alopecia areata can lower quality of life.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.
research Incipient Diabetes Mellitus and Nascent Thyroid Disease Presenting as Beard Alopecia Areata: Case Report and Treatment Review of Alopecia Areata of the Beard
Beard hair loss can signal early diabetes and thyroid issues, treatable with specific cream.
research Causal Relationship and Potential Common Pathogenic Mechanisms Between Alopecia Areata and Related Cancer
Alopecia areata might help slow down certain cancers.
research Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
The study assessed the long-term efficacy and safety of ritlecitinib in 191 patients aged ≥12 years with alopecia areata and significant scalp hair loss over 3 years. Results showed that 65.1% of patients achieved a SALT score ≤20, indicating significant hair regrowth, and 31.2% achieved complete scalp hair regrowth. The treatment was well-tolerated, with a safety profile consistent with previous studies. Factors such as female sex, White race, and shorter duration of hair loss were associated with better treatment response. These findings support the long-term use of ritlecitinib for severe alopecia areata in patients aged ≥12 years.
research The efficacy and safety of tofacitinib in patients with alopecia totalis
Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.